{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T18:08:50Z","timestamp":1778782130611,"version":"3.51.4"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,14]]},"DOI":"10.7759\/cureus.108850","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T17:16:16Z","timestamp":1778778976000},"source":"Crossref","is-referenced-by-count":0,"title":["Biologic Therapy in Ulcerative Colitis: A Retrospective Real-World Study in a Brazilian Tertiary University Hospital"],"prefix":"10.7759","author":[{"given":"Helena M","family":"Varandas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Clara M","family":"Varandas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cintia M","family":"Clemente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2022.100298","article-title":"Temporal trends in the epidemiology of inflammatory bowel diseases in the public healthcare system in Brazil: a large population-based study","volume":"13","author":"Quaresma AB","year":"2022","unstructured":"Quaresma AB, Damiao AO, Coy CS, et al.. Temporal trends in the epidemiology of inflammatory bowel diseases in the public healthcare system in Brazil: a large population-based study. Lancet Reg Health Am. 2022, 13:100298. 10.1016\/j.lana.2022.100298","journal-title":"Lancet Reg Health Am"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1590\/S0004-2803.202203000-60","article-title":"Incidence, prevalence, and epidemiological characteristics of inflammatory bowel diseases in the state of Paran\u00e1 in southern Brazil","volume":"59","author":"Renuzza SS","year":"2022","unstructured":"Renuzza SS, Vieira ER, Cornel CA, Lima MN, Ramos Junior O. Incidence, prevalence, and epidemiological characteristics of inflammatory bowel diseases in the state of Paran\u00e1 in southern Brazil. Arq Gastroenterol. 2022, 59:327-33. 10.1590\/S0004-2803.202203000-60","journal-title":"Arq Gastroenterol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner D","year":"2021","unstructured":"Turner D, Ricciuto A, Lewis A, et al.. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021, 160:1570-83. 10.1053\/j.gastro.2020.12.031","journal-title":"Gastroenterology"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000003463","article-title":"ACG clinical guideline update: ulcerative colitis in adults","volume":"120","author":"Rubin DT","year":"2025","unstructured":"Rubin DT, Ananthakrishnan AN, Siegel CA, Barnes EL, Long MD. ACG clinical guideline update: ulcerative colitis in adults. Am J Gastroenterol. 2025, 120:1187-224. 10.14309\/ajg.0000000000003463","journal-title":"Am J Gastroenterol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2024.10.001","article-title":"AGA living clinical practice guideline on pharmacological management of moderate-to-severe ulcerative colitis","volume":"167","author":"Singh S","year":"2024","unstructured":"Singh S, Loftus EV Jr, Limketkai BN, Haydek JP, Agrawal M, Scott FI, Ananthakrishnan AN. AGA living clinical practice guideline on pharmacological management of moderate-to-severe ulcerative colitis. Gastroenterology. 2024, 167:1307-43. 10.1053\/j.gastro.2024.10.001","journal-title":"Gastroenterology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine T","year":"2022","unstructured":"Raine T, Bonovas S, Burisch J, et al.. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2022, 16:2-17. 10.1093\/ecco-jcc\/jjab178","journal-title":"J Crohns Colitis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izad245","article-title":"Real-world persistence of successive biologics in patients with inflammatory bowel disease: findings from ROTARY","volume":"30","author":"Krugliak Cleveland N","year":"2024","unstructured":"Krugliak Cleveland N, Ghosh S, Chastek B, et al.. Real-world persistence of successive biologics in patients with inflammatory bowel disease: findings from ROTARY. Inflamm Bowel Dis. 2024, 30:1776-87. 10.1093\/ibd\/izad245","journal-title":"Inflamm Bowel Dis"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastrohep.2025.502396","article-title":"Clinical effectiveness and safety of vedolizumab versus infliximab in biologic-na\u00efve patients with ulcerative colitis: a comparative real-world multicentric observational study","volume":"48","author":"da Costa Ferreira S","year":"2025","unstructured":"da Costa Ferreira S, Parra RS, Sassaki LY, et al.. Clinical effectiveness and safety of vedolizumab versus infliximab in biologic-na\u00efve patients with ulcerative colitis: a comparative real-world multicentric observational study. Gastroenterol Hepatol. 2025, 48:502396. 10.1016\/j.gastrohep.2025.502396","journal-title":"Gastroenterol Hepatol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16952","article-title":"Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression-risks, screening, diagnosis and management","volume":"56","author":"Fehily SR","year":"2022","unstructured":"Fehily SR, Al-Ani AH, Abdelmalak J, et al.. Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression-risks, screening, diagnosis and management. Aliment Pharmacol Ther. 2022, 56:6-27. 10.1111\/apt.16952","journal-title":"Aliment Pharmacol Ther"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1590\/S0004-2803.24612023-148","article-title":"Rate of infection (tuberculosis) in Brazilians IBD private patients: follow-up 15 years","volume":"61","author":"Cury DB","year":"2024","unstructured":"Cury DB, Cury LC, Micheletti AC, Oliveira RA, Gon\u00e7alves JJ. Rate of infection (tuberculosis) in Brazilians IBD private patients: follow-up 15 years. Arq Gastroenterol. 2024, 61:e23148. 10.1590\/S0004-2803.24612023-148","journal-title":"Arq Gastroenterol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/17562848231179871","article-title":"Active tuberculosis in inflammatory bowel disease patients: a case-control study","volume":"16","author":"Freitas Cardoso de Azevedo M","year":"2023","unstructured":"Freitas Cardoso de Azevedo M, Barros LL, Fernandes Justus F, et al.. Active tuberculosis in inflammatory bowel disease patients: a case-control study. Ther Adv Gastroenterol. 2023, 16:17562848231179871. 10.1177\/17562848231179871","journal-title":"Ther Adv Gastroenterol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad108","article-title":"ECCO guidelines on extraintestinal manifestations in inflammatory bowel disease","volume":"18","author":"Gordon H","year":"2024","unstructured":"Gordon H, Burisch J, Ellul P, et al.. ECCO guidelines on extraintestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2024, 18:1-37. 10.1093\/ecco-jcc\/jjad108","journal-title":"J Crohns Colitis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1159\/000341950","article-title":"Treatment of extraintestinal manifestations in inflammatory bowel disease","volume":"86 Suppl 1","author":"Lakatos PL","year":"2012","unstructured":"Lakatos PL, Lakatos L, Kiss LS, Peyrin-Biroulet L, Schoepfer A, Vavricka S. Treatment of extraintestinal manifestations in inflammatory bowel disease. Digestion. 2012, 86 Suppl 1:28-35. 10.1159\/000341950","journal-title":"Digestion"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2017.15.4.434","article-title":"Medication adherence in inflammatory bowel disease","volume":"15","author":"Chan W","year":"2017","unstructured":"Chan W, Chen A, Tiao D, Selinger C, Leong R. Medication adherence in inflammatory bowel disease. Intest Res. 2017, 15:434-45. 10.5217\/ir.2017.15.4.434","journal-title":"Intest Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts P","year":"2005","unstructured":"Rutgeerts P, Sandborn WJ, Feagan BG, et al.. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005, 353:2462-76. 10.1056\/NEJMoa050516","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan BG","year":"2013","unstructured":"Feagan BG, Rutgeerts P, Sands BE, et al.. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013, 369:699-710. 10.1056\/NEJMoa1215734","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn WJ","year":"2012","unstructured":"Sandborn WJ, van Assche G, Reinisch W, et al.. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012, 142:257-65.e1-3. 10.1053\/j.gastro.2011.10.032","journal-title":"Gastroenterology"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1905725","article-title":"Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis","volume":"381","author":"Sands BE","year":"2019","unstructured":"Sands BE, Peyrin-Biroulet L, Loftus EV Jr, et al.. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med. 2019, 381:1215-26. 10.1056\/NEJMoa1905725","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/479375-biologic-therapy-in-ulcerative-colitis-a-retrospective-real-world-study-in-a-brazilian-tertiary-university-hospital","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T17:16:17Z","timestamp":1778778977000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/479375-biologic-therapy-in-ulcerative-colitis-a-retrospective-real-world-study-in-a-brazilian-tertiary-university-hospital"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.108850","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,14]]}}}